Altrova Health reported its first significant commercial revenue of $112,000 for the nine months ended June 30, 2026, up from $15,551 the previous year, reflecting successful distribution and commercialization efforts. The company expanded its partnerships and product offerings, including NIRLAB device sales and plans to relaunch rapid detection strips. Despite an increased net loss of $2.35 million due to non-cash charges and share-based compensation, operational costs remained controlled. This marks a key growth phase as Altrova builds momentum in its healthcare product portfolio and commercial network.
Utility stocks Edison International and PG&E Corporation fell sharply after California lawmakers passed wildfire legislation without expected liability protections, exposing utilities to costly claims. Edison dropped over 23%, nearing its 52-week low...
Several stocks saw significant gains due to recent financing disclosures, new analyst coverage, and leadership appointments. Antelope Enterprise Holdings rose 83% after raising nearly $19 million in a private placement. Ticketplus jumped 31% followin...
Scotiabank increased its price target for Palo Alto Networks to $430, suggesting a 13% upside from current levels, following a 30% surge in shares after strong Q3 results. The cybersecurity firm is expected to deliver robust Q4 performance and signif...
First Majestic Silver Corp. has been upgraded to a Hold rating due to a fair valuation and improved operational outlook, driven by increased gold and silver demand. The company’s production guidance now expects gold output to rise by 30% through 2028...
A class action lawsuit has been filed against Innventure, Inc. by investors who bought shares between November 2025 and August 2026. The suit alleges that Innventure misled investors about a major deal involving its subsidiary Accelsius and DarkNX to...
